Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer
November 03 2016 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of hematology
and oncology therapeutics that address unmet medical needs, today
announced that Stephen F. Ghiglieri has been appointed as the
Company’s Executive Vice President and Chief Financial Officer,
effective immediately.
“Stephen has 30 years of senior level finance and operating
experience, primarily in the life sciences industry, and has been
integral to the growth of numerous companies, from emerging stage
through commercial approval and market launch,” said Mark W.
Schwartz, Ph.D., President and Chief Executive Officer.
“Stephen is a welcome addition to our management team as we
restructure our organization and position ourselves to progress our
rich clinical pipeline. We are preparing to initiate a
pivotal trial next year, and we look forward to providing a
corporate update on the progress of all of our programs on our
quarterly call next week.”
“I am excited to be joining Galena at this important time in the
Company’s history. Galena is currently re-focusing its
efforts with a backbone of valuable hematology and immunotherapy
assets. I welcome the opportunity to join the team and provide
guidance and leadership to help advance the company through its
next stages of development. I believe we have the opportunity to
build significant shareholder value by executing on a relatively
lower risk clinical and regulatory development program with
GALE-401 and supporting ongoing investigator and partner sponsored
studies with our immunotherapy assets,” commented, Mr.
Ghiglieri.
Stephen F. Ghiglieri joins Galena Biopharma with more than 30
years in senior level finance and operations roles at both
biotechnology and technology companies. Prior to Galena
Biopharma, Mr. Ghiglieri served as CFO of MedData Inc., a private
equity backed healthcare services company that was sold to Mednax,
a publicly traded national medical group. Previously, he
spent nearly 10 years at NeurogesX, ending his tenure as the
Company’s Executive Vice President, Chief Operating Officer, and
CFO. Prior to that he served as the CFO of Hansen Medical,
Inc., a medical device company. He also held senior level
finance positions at two other healthcare companies: Oacis
Healthcare Systems, Inc., and Oclassen Pharmaceuticals, Inc.
Additionally, he was also the CFO and Corporate Secretary for two
technology software companies: Avolent, Inc., and Andromedia, Inc.
Mr. Ghiglieri began his career as an audit manager of
PricewaterhouseCoopers, LLP. He received a Bachelor of Science in
Business Administration from California State University, Hayward
where he graduated Magna Cum Laude. Mr. Ghiglieri is also a
Certified Public Accountant (inactive).
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of hematology and oncology
therapeutics that address unmet medical needs. Galena’s pipeline
consists of multiple mid-to-late-stage clinical assets led by its
hematology asset, GALE-401, and novel cancer immunotherapy programs
including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more
information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the development of Galena’s
product candidates, patient enrollment in our clinical trials, as
well as other statements related to the progress and timing of our
development activities, present or future licensing, collaborative
or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates
or that otherwise relate to future periods. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those identified under “Risk Factors” in
Galena’s Annual Report on Form 10-K for the year ended December 31,
2015 and most recent Quarterly Reports on Form 10-Q filed with the
SEC. Actual results may differ materially from those contemplated
by these forward-looking statements. Galena does not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024